Bank of New York Mellon Corp Grows Stake in Renovaro Inc. (NASDAQ:RENB)

Bank of New York Mellon Corp lifted its stake in Renovaro Inc. (NASDAQ:RENB) by 137.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 223,915 shares of the company’s stock after buying an additional 129,529 shares during the period. Bank of New York Mellon Corp owned approximately 0.14% of Renovaro worth $187,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of RENB. State Street Corp lifted its position in Renovaro by 3.8% during the 3rd quarter. State Street Corp now owns 1,323,832 shares of the company’s stock worth $640,000 after acquiring an additional 48,114 shares in the last quarter. Barclays PLC raised its stake in shares of Renovaro by 315.7% during the third quarter. Barclays PLC now owns 69,531 shares of the company’s stock valued at $34,000 after purchasing an additional 52,804 shares during the period. JPMorgan Chase & Co. lifted its position in shares of Renovaro by 347.6% during the third quarter. JPMorgan Chase & Co. now owns 93,010 shares of the company’s stock worth $45,000 after purchasing an additional 72,230 shares in the last quarter. SG Americas Securities LLC boosted its stake in shares of Renovaro by 193.3% in the fourth quarter. SG Americas Securities LLC now owns 51,725 shares of the company’s stock valued at $43,000 after purchasing an additional 34,090 shares during the period. Finally, Rhumbline Advisers grew its holdings in Renovaro by 122.6% during the 4th quarter. Rhumbline Advisers now owns 112,960 shares of the company’s stock valued at $94,000 after purchasing an additional 62,204 shares in the last quarter. Institutional investors and hedge funds own 71.41% of the company’s stock.

Renovaro Price Performance

Shares of RENB stock opened at $0.58 on Friday. The company’s fifty day moving average price is $0.80 and its two-hundred day moving average price is $0.79. The firm has a market capitalization of $92.06 million, a P/E ratio of -0.62 and a beta of 0.42. Renovaro Inc. has a 12 month low of $0.40 and a 12 month high of $3.05.

Renovaro (NASDAQ:RENB) last announced its earnings results on Wednesday, February 19th. The company reported ($0.02) earnings per share (EPS) for the quarter.

About Renovaro

Renovaro Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company’s product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV.